Personalised medicine has predominantly focused on genetically-altered cancer genes that 28 stratify drug responses, but there is a need to objectively evaluate differential pharmacology 29 patterns at a subpopulation level. Here, we introduce an approach based on unsupervised 30 machine learning to compare the pharmacological response relationships between 327 pairs 31 of cancer therapies. This approach integrated multiple measures of response to identify 32 subpopulations that react differently to inhibitors of the same or different targets to 33 understand mechanisms of resistance and pathway cross-talk. MEK, BRAF, and PI3K 34
Abstract 27
Personalised medicine has predominantly focused on genetically-altered cancer genes that 28 stratify drug responses, but there is a need to objectively evaluate differential pharmacology 29 patterns at a subpopulation level. Here, we introduce an approach based on unsupervised 30 machine learning to compare the pharmacological response relationships between 327 pairs 31 of cancer therapies. This approach integrated multiple measures of response to identify 32 subpopulations that react differently to inhibitors of the same or different targets to 33 understand mechanisms of resistance and pathway cross-talk. MEK, BRAF, and PI3K 34
inhibitors were shown to be effective as combination therapies for particular BRAF mutant 35 subpopulations. A systematic analysis of preclinical data for a failed phase III trial of 36 selumetinib combined with docetaxel in lung cancer suggests potential indications in 37 urogenital and colorectal cancers with KRAS mutation. This data-informed study exemplifies 38 a method for stratified medicine to identify novel cancer subpopulations, their genetic 39 biomarkers, and effective drug combinations. Drug developers face a conundrum in predicting the efficacy of their investigational 48 compound compared to existing drugs used as the standard of care treatment. Systematic 49 screening of drug compounds across a variety of genomic backgrounds in cancer cell lines 50 has improved clinical trial design and personalized treatments 1 . Following the pioneering 51 NCI-60 screen comprised of 59 unique cell lines 2 , modern high-throughput screens such as 52
the Genomics of Drug Sensitivity in Cancer (GDSC) 3,4 , the Cancer Cell Line Encyclopedia 53 (CCLE) 5 and the Cancer Therapeutics Response Portal (CTRP) 6-8 have characterised 54 >1,000 cancer cell lines with the goal of establishing the genetic landscape of cancer. The 55
deep molecular characterisation of these large cell line panels is complemented with high-56
throughput drug screens, which enables the discovery of drug response biomarkers. For 57 example, analysis of the generic BRAF inhibitors PLX4720, SB590885 and CI-1040 58
reproduced drug sensitivity association with BRAF mutation in melanoma, or afatinib 59 sensitivity with ERBB2 amplifications in breast cancer 3,4,9 . These associations between 60 genetic variants and treatment response have helped identify specific patient subpopulations 61
who are most likely to benefit from treatment. In Phase III clinical trials, however, for new 62 drugs to be successful, they must demonstrate a significant improvement over the existing 63 standard of care. Accurately defining in which subpopulations a new drug demonstrates 64
improved differential efficacy over other drugs targeting the same disease could lead to both 65
better clinical outcomes as well as new targeted therapies. 66 67
While several methods have been proposed to identify drug response biomarkers in cell 68 lines for precision medicine and drug repositioning 4,5,10,11 , there is a need for more objective 69
and unsupervised approaches for identifying subpopulations with differences in drug 70 response (differential drug response), and consequently systematically gain mechanistic 71 insights from biomarkers. Most approaches capable of comparing multiple drugs measure 72 the overall similarity (or correlation) based on a single response summary metric 7,12 , which 73 permits drug repositioning based on subpopulations with similar behavior, but neglects ones 74 that behave differently (Figure S1A) . Here, we used an unsupervised technique to identify 75 the perimeters of differentially sensitive or resistant subpopulations and which may be 76 generalized to stratify the pharmacology response for any pair (or n-tuple) of targets using 77 any number of drug response summary metrics (e.g. IC 50 or AUC). Segmentation of the 78 overall population occurs top-down and along globally-optimal contours that are derived 79 explicitly and maximize the differences between the two resulting subpopulations. The 80 segmentation continues recursively and is modulated by multiple user-defined criteria such 81
as the size or separability of the resulting subpopulations. Higher threshold values for both 82 result in less granular subpopulations but increase certainty that the subpopulations and the 83 quantities estimated from them are both distinct and accurate. 84 85 We present results from our platform, SEABED (SEgmentation And Biomarker Enrichment 86
of Differential treatment response), to demonstrate how unsupervised machine learning can 87 discover intrinsic partitions in the drug response measurements of two or more drugs that 88 directly correspond to distinct pharmacological patterns of response with therapeutic 89
biomarkers. Addressing the challenges in comparing the response of two drugs, SEABED 90 initially assesses two gold standards with established clinical biomarkers, namely the 91 differential response of a BRAF inhibitor and MEK inhibitor with anticipated BRAF and KRAS 92 mutations [13] [14] [15] [16] , and an EGFR inhibitor and MEK inhibitor with expected biomarkers of 93 EGFR, ERBB2 and KRAS mutations 17-20 . Next, we systematically compare how different 94 drugs targeting the MAPK and PI3K-AKT pathway yield different patterns of response within 95 subpopulations. We show how differential drug response may indicate benefit for drug 96 combinations explained through independent action rather than probable synergy by 97 examining subpopulations uniquely sensitive to a single drug 21 , which may be precisely 98 targeted by identified biomarkers. Finally, we demonstrate how the analysis of differential 99 response can guide the design of clinical trials by revealing specific indications where an 100 investigational therapy may be more effective than the standard treatment. 101
102

Results
104
We applied our technique to discover subpopulations of cell lines in which two or more 105 compounds, possibly addressing the same disease state or even targeting the same genetic 106 alteration, have a common pharmacological pattern of response. By further associating 107 enriched genetic alterations in subpopulations with specific patterns of response, we shed 108 light into molecular mechanisms responsible for patient subpopulations that respond 109 differently to two drugs. 110 111
Identifying subpopulations of differential drug response 112
We first considered the specific circumstance in which two drugs engage different targets 113
within the same signalling pathway, namely agents targeting MAPK signaling. SEABED used 114 nearly 1,000 cancer cells derived from the GDSC database, and we evaluated two 115 established drug response measures: the drug concentration required to reduce cell viability 116
by half (IC 50 ) and the area under the dose-response curve (AUC; Figure 1A) . SEABED 117 employed a multivariate similarity measure to compare the vector patterns of response for 118 each distinct pair of cell lines without requiring a priori assumptions on the number or 119
distribution of the subpopulations. The result is a diverse cell line population segmented into 120 distinct subpopulations having homogeneous patterns of drug response (Figure 1B) . Here 121 exemplified, we show that the drug response of 802 cell lines treated with either SB590885 122 (BRAF inhibitor) or CI-1040 (MEK inhibitor) could be segmented into 7 distinct 123 subpopulations with a median size of 40 cell lines by integrating the two metrics of drug 124 response, AUC and IC 50 ( Figure 1C ; see Figures S1B and S1C for individual cell lines 125 segmented by IC 50 and AUC respectively). We comprehensively evaluate pan-cancer 126 somatic events to nominate biomarkers (see Methods) 4 , and found that the subpopulation 127 sensitive to both inhibitors was significantly enriched for BRAF mutants (P=3.87e-14, 128 hypergeometric test), while another subpopulation was exclusively sensitive to the MEK 129
inhibitor and significantly enriched for KRAS mutations (P=0.00589, hypergeometric test). 130 131
In another example we examined a case where one inhibitor might overcome resistance to 132 another inhibitor targeting the same pathway; AZD6244/ARRY-142886 selumetinib (MEK 133 inhibitor) with afatinib (EGFR and ERBB2 dual inhibitor) across 839 cell lines ( Figure 1D ).
134
Strong markers of sensitivity for selumetinib are subpopulations carrying known associated 135 KRAS, NRAS and BRAF mutations (Figures 1D and 1E) . A less anticipated association is 136
APC loss-of-function sensitivity to selumetinib, albeit this was also found with trametinib 137
(another MEK inhibitor) in APC deficient mice 22 . We reproduced the well-established 138 associations of afatinib with either EGFR and ERBB2 amplifications 4,23 , and surprisingly our 139 unsupervised segmentation returned two subpopulations enriched for EGFR amplifications. 140
The more sensitive subpopulation is solely enriched for EGFR amplifications, whilst the less 141 sensitive subpopulation additionally includes activating PIK3CA mutations. In concordance 142
with recent literature, PI3K-AKT signaling drives acquired drug resistance to EGFR inhibitors 143 in lung cancer 24 . 144 145
Drug response segmentation resulted in 14 subpopulations with a median size of 37 ( Figure  146 1D). The subpopulation enriched for EGFR, ERBB2 and PI3KCA variants, has an average 147 log(IC 50 ) of 1.01µM for selumetinib and -0.672µM for afatinib. In contrast, the BRAF mutation 148
was enriched in a subpopulation where the average log(IC 50 ) for selumetinib was -1.097µM 149 and 0.625µM for afatinib. The difference in response between afatinib and selumetinib was 150 significantly greater (t-test P<0.01) between the subpopulations identified and the total 151 population of PIK3CA or BRAF mutant cell lines (Figures 1F and 1G ).
153
Cross-comparison of multiple drugs redefines best-in-class drugs for specific 154 subpopulations 155
Although there is a larger portfolio of clinical drugs with identical putative targets, their 156
responses may differ substantially in subpopulations as a consequence of multiple factors, 157
for example mode-of-action, different off-target effects and binding properties. The ability to 158 discover cell line subpopulations with distinct pharmacological patterns of response 159 characterised by genetic mutations re-defines best-in-class drugs by their differential 160 response to other drugs in a specific subpopulation, rather than their absolute response 161
across an entire population. 162 163
In order to demonstrate this approach for drug discovery, we applied SEABED to 745 cell 164 lines across cancer types to evaluate the differential response in those cell lines to five 165 inhibitors (CI-1040, PD0325901, RDEA119, selumetinib, and trametinib) which all target the 166 MEK protein (Figure 2A) . The segmentation of cell lines revealed 13 subpopulations with 167 different patterns of response and three having enriched biomarkers ( Figure S2A ). Two 168
subpopulations were sensitive to all MEK inhibitors, with trametinib achieving the greatest 169 sensitivity. In one subpopulation the KRAS mutation was enriched (Fisher exact p-value = 170
1.12e-4 and 40.8% of the cell lines) while another had the BRAF mutation enriched (Fisher 171 exact p-value = 1.39e-7 and 50% of the cell lines). In contrast, another subpopulation was 172 enriched with the RB1 mutation (Fisher exact p-value = 3.84e-2 and 21.6% of cell lines), 173
within which the cell lines were almost uniformly resistant to all MEK inhibitors. 174 175
Distribution of subpopulations highlight distinct pharmacological relationships 176 between PI3K-AKT and MAPK signaling 177
Next, we used SEABED to investigate the cross-talk between two frequently active cancer 178 pathways, MAPK and PI3K-AKT signalling, by systematically comparing pairs of drugs 179
targeting different genes of each pathway (Figure 2A classified the distribution of subpopulations based on somewhat arbitrary thresholds for 187 sensitivity, we also measured the weighted average Pearson correlation across 188 subpopulations to identify interesting drug pairs ( Figure S3 ).
190
We found 20 drug pairs subpopulations with sensitivity to both PI3K- AKT (Website S1; https://szen95.github.io/SEABED). 212 213
Subpopulations of differential response identifies drug combination efficacy 214
Previous studies have hypothesised that the efficacy of many approved drug combinations 215
can be explained by the independent action of single agents on different patient 216 subpopulations with cancers driven by multiple pathways 21 . We hypothesised that SEABED 217
comparisons of drug pairs would highlight subpopulations of differential response that would 218 exhibit synergistic or independent action effects when the drugs are tested in combination.
219
Additionally, our method enables to explore putative biomarkers of such populations. 220
Systematic comparison of responses between two drugs highlighted subpopulations of cell 221 lines in which there was sensitivity to either drug but not both (divergent response). We Two subpopulations with a high proportion of BRAF mutations were identified with greater 228 sensitivity to the BRAF inhibitor ( Figure 3B ). These two subpopulations had a combined 229 total of 79 cell lines ( Figure 3C) . The subpopulation with an average log(IC 50 ) of -0.0232µM 230 for PLX4720-2 and 0.771µM for PI-103 had 21 cell lines with BRAF mutation (87.5%; 231
P=9.75e-17). In contrast, the subpopulation with an average log(IC 50 ) of 0.808µM for 232 PLX4720-2 and 0.562µM for PI-103 had 22 cell lines with BRAF mutation (40.4%; P=5.12e-233 7) ( Figure 3B ). We observed 17 individual cell lines with BRAF mutation that are resistant to 234 both drugs ( Figure S4G ).
236
We next examined the drug pairs as combination therapies in cell lines 25 and patient-237 derived tumor xenograft models (PDXs) 26 to investigate whether the drug pairs with 238 divergent response and subpopulations with preferential sensitivity to one drug would be 239 associated with efficacy of their combination treatment ( Figure 3D ). SEABED first compared 240 the single drug responses of BRAF, MEK and PI3K inhibitors as before to identify BRAF 241 mutant subpopulations with differential response. When the drugs were tested as 242 combinations in BRAF mutant cell lines, the MEK/PI3K inhibitor combination had a surprising 243 similar level of synergy as BRAF/MEK combinations, which was recently a clinically 244 approved combination 27,28 . Also surprising, these two combinations had significantly higher 245 synergistic effect when used on BRAF mutant cell lines compared to all cell lines (t-test 246 P=0.0204), and compared to all drug combinations tested (t-test P=1.46e-5; Figure 3E ; 247 Figure S4H ). In terms of overall efficacy in PDXs, we observed a similar level of inhibition to 248 tumour volume for the BRAF/PI3K inhibitor combination on BRAF mutant cells when 249 compared to the clinically approved BRAF/MEK combination and a significantly greater (t-250 test P=0.0418) inhibition of tumour growth compared to all combinations ( Figure 3F ; Figure  251 S4I). Notably, previous work suggested in vivo efficacy of drug combinations is mostly driven 252 by the monotherapy agents targeting independent mechanisms 26 ; however, they did not 253 exclude the possibility that such drug combinations may also be synergistic. Here, we 254 highlight a drug combination example, where in vivo efficacy is driven by targeting 255 independent mechanisms, and complementary being synergistic. This example highlights 256 that both concepts, synergy and targeting independent mechanism may contribute to 257 combination efficacy in patients.
259
Lack of subpopulations of differential response may explain clinical failure 260
Sometimes, despite strong preclinical evidence, some drugs do not succeed in clinical trials 261 29 . One such trial was SELECT-1 (Table S1 ) which compared the efficacy of combining 262 selumetinib and docetaxel to docetaxel alone in patients with advanced KRAS-mutant non-263 small cell lung cancer (NSCLC) 30 . Although there were KRAS mutant cell lines sensitive to 264 selumetinib in preclinical testing 31 , we re-examined the pharmacological data with SEABED 265
to assess whether there were distinct subpopulations that justified the patient selection 266 criteria for KRAS mutation. 267 268
In this analysis, instead of only inspecting the subpopulation identified by SEABED when the 269 segmentation algorithm terminated, we thoroughly examined all possible subpopulations.
270
SEABED identified a total of 61 possible subpopulations from 840 cell lines across tissue 271
types tested with selumetinib and docetaxel ( Figure 4A) . 10 subpopulations were more 272 sensitive to selumetinib than docetaxel ( Figure 4B) , and 5 of those subpopulations were 273 enriched for KRAS mutation. However, those subpopulations enriched for NSCLC KRAS 274 mutants were small in size and mostly exhibited less sensitivity to selumetinib compared to 275 docetaxel (Figures S5A and S5B) . Next, we focused on subpopulation_60, which had the greatest difference in sensitivity (IC 50 283
and AUC) to selumetinib compared to docetaxel (Figure 4C ). This subpopulation of 122 cell 284 lines was enriched in KRAS mutations (28.8%, P=3.061e-4) found across multiple tissue 285
types. NSCLC cell lines accounted for only 8% of this subpopulation, with 50% of those cell 286 lines being KRAS mutants. Colorectal and pancreatic cell lines accounted for 15% and 8% 287
respectively of the subpopulation, and they both had a higher proportion of KRAS mutations 288 (56% and 100% respectively; Figure 4D ).
290
Discussion 291 292
The ability to identify distinct subpopulations based on multiple measures of drug response 293 (eg. IC 50 and AUC) and extract their biomarkers is the basis for personalised therapeutics, 294
which may ultimately increase the likelihood of successful clinical trials 32,33 . Using a 295
network-based segmentation algorithm coupled with biomarker detection (SEABED), we 296 investigated well-established pharmacological targets and clinical biomarkers by comparing 297 the response patterns for BRAF (SB590885) and MEK (CI-1040) inhibition, which expectedly 298
reproduced subpopulations sensitive to both enriched for BRAF mutants 34-36 . In another 299 example, SEABED compared EGFR/ERBB2 (afatinib) and MEK (selumetinib) inhibition to 300
reveal expected biomarkers such as BRAF, KRAS and NRAS mutations for selumetinib 13-16 , 301
and afatinib associated with EGFR and ERBB2 amplifications 37,38 . Interestingly, the more 302 afatinib-resistant subpopulation was enriched for PI3KCA-activating mutation, which may 303 cause acquired resistance 24 . When we systematically compared inhibitors of the MAPK and 304
PI3K-AKT signaling pathways, we observed subpopulations sensitive to both CRAF, ERK or 305
RSK targeted drugs and other drugs targeting the PI3K-AKT pathway, however, there were 306 few instances of these subpopulations for inhibitors targeting other genes in the MAPK 307 signalling 39 . We found many more subpopulations that were more sensitive to BRAF 308
inhibitors than other PI3K-AKT inhibitors, and as expected, many contained BRAF mutations 309 34 . In contrast, there were not significantly more subpopulations sensitive to MEK inhibition 310 compared to inhibition of PI3K-AKT signalling targets, but BRAF mutant subpopulations may 311 have greater differential response 14 . Divergent response was observed when comparing 312 EGFR, BRAF and MEK inhibitors to drugs targeting the PI3K-AKT pathway. Our results 313 comparing the MAPK and PI3K-AKT pathways based on drug response profiles highlights 314
how intertwined those two pathways are in pharmacology space 39 . 315 316
Arguably, the divergent response type is the most exciting for personalised treatment, since 317 it may identify cases where independent drug action and synergy may guide effective drug 318 combinations 21 . Here exemplified, we showed that PI3K inhibitors combined with either 319 BRAF or MEK inhibitors increase in vitro synergy and reduce tumour volume of in-vivo 320
models. Furthermore, we were able to show that synergistic and overall effect can be further 321 enhanced by the correct biomarker indication, in this instance, BRAF mutant subpopulations 322 40, 41 . The BRAF mutant subpopulation with high efficacy for the BRAF inhibitor and not the 323 other inhibitor could be cases where independent drug action explains drug combination 324 efficacy, whereas, the subpopulation with lower efficacy for single treatments of either drug 325 may be cases for synergistic effects when the drugs are combined. 326 327
In examining the preclinical evidence for trial testing combination treatment of NSCLC in 328 which the KRAS mutation was the biomarker 42 , SEABED revealed a high proportion of 329 NSCLC subpopulations having the KRAS mutation that are resistant to both selumetinib and 330
docetaxel, suggesting a smaller likelihood of efficacy for the drug combination. Alternately, 331
we identified a subpopulation with differential response to selumetinib for a small proportion 332
of KRAS NSCLC cell lines, but this subpopulation contained a higher proportion of colorectal 333
and pancreatic cancer cells with KRAS mutations. Previous studies have shown the 334 plausibility in treating colorectal cancer using MEK inhibitor combinations 43, 44 . With 335 consideration of KRAS mutations in subpopulations having greater sensitivity to selumetinib, 336
SEABED suggests that while the correct biomarker was used for the clinical trial, there may 337 be other potential indications for selumetinib. Although response in cell lines may not always 338 correspond to response clinically, the use of data-informed approaches to examine large 339 populations of cells may reveal clinically relevant drug response patterns. Future studies 340 may need to account for differences between in vitro and in vivo responses. 341 342
While iterative and hierarchical clustering techniques have been used widely to attribute 343 molecular markers to differences in subpopulation drug response and outcomes 45,46 , we use 344
an approach that does not require an explicit estimate of the number of subpopulations and 345
is not greedy, i.e., each incremental step is optimal but the overall algorithm is not. In 346 biomedical data processing, there has been substantial concern, particularly regarding 347 applications to molecular data, that rival unsupervised machine learning optimize different 348 criteria and consequently yield diverging answers 47,48 . In our effort, we are concerned with 349 discovering subpopulations having high homogeneity and statistical separability, while 350
avoiding subpopulations that are so small that extracting statistically significant biomarkers is 351
unlikely. We demonstrated the utility of SEABED over conventional approaches of K-Means 352
and hierarchical clustering for drug response comparisons (see Supplementary Materials,  353  Table S2 , Table S3 , and Figure S6) As a whole, this study demonstrates several important insights about the pharmacological 370 pattern of response for different cancer drugs by applying an unsupervised machine learning 371 platform to segment a large pan-cancer in vitro pharmacology data set. By organizing cell 372 lines along similar pharmacological patterns of response, we identified distinct, intrinsic 373 subpopulations sensitive to one drug but resistant to others, and in some cases identified 374 genetic alterations that can be used as biomarkers for those subpopulations. In the context 375 of analytical frameworks for increasing drug R&D productivity by sharpening the focus of 376 drugs 58 , our work demonstrates the value of advanced analytical approaches in translational 377 medicine to enable decision making that is more data-informed and less ambiguous. 378
Moreover, by analyzing different pharmacological responses and interpreting its outputs in 379 the context of the underlying genetics and molecular pathways, we have created a multi- For a given cell line in GDSC, the drug response was fitted with a sigmoid curve 59 and 403 consecutively quantified as area under the curve (AUC) or the concentration required to 404 reduce cell viability by half (IC 50 ). GDSC contains 265 compounds tested in 1074 cell lines, 405
whilst we focus on a subset of 38 drugs targeting either the PI3K-AKT or MAPK signalling, 406
which leads to 327 experiments considered for evaluation. 407 408
Deep molecular characterisation of the cancer cell lines 409
The GDSC project 4 provides the characterisation of >1,000 cell lines including whole exome 410 sequencing, targeted PCR sequencing/split probe FISH analysis and SNP6.0 arrays, which 411 enabled to quantify somatic mutations, gene fusions and copy number variations (CNVs), 412
respectively. In our analysis, we focus on somatic mutational state of 300 cancer genes and 413 10 gene fusions. Additionally, we considered 425 recurrent CNVs, split into 117 414 amplifications and 308 deletions. In total, we consider 735 cancer functional events, which is 415 summarized in the binary event matrix (BEM) from Iorio et al. 4 . 416 417
Pre-processing cell line and pharmacological data 418
For every pair of drugs that was computationally analyzed, the subset of GDSC cell lines 419
having valid IC 50 and AUC values for both drugs was retained. Typically there were roughly 420 700 cell lines across all cancer types that met these criteria in each experiment. Cancer 421 types and subtypes were stored along with the pharmacological data in a table for each drug  422 for subsequent recall and analysis. 423 424
Processing drug response measures (AUC/IC 50 values) 425 We build network models for a set of cell lines, = { , . . , }, that are separately 426 exposed to two distinct drugs, and , which results in two sets of measurement 427 variables, = [ , . . , ], = 1,2, describing the response to each compound: 428 429 , = ( ), = 1,2; = 1, . . . , (Equation 1) 430 431
We use a network model that is an undirected graph, , consisting of vertices, , = 432 1, . . . , , (one for each cell line in ) with weighted edges, , ( , ), , = 1, . . . , , ≠ , 433
between every distinct pair of vertices. Our approach 434 uses a single multivariate similarity measure (Equation 2), to construct one network model, 435
with the advantage that the subspace properties of the resulting adjacency and Laplacian 436
matrices are fully embedded with the complete characteristics of . The weight is the 437 similarity, w i,j , between -th and -th composite 2 1 dose response profile (DRP), = 438
[ , , , ], for and .
440
We characterize drug response by two important continuous-valued measurements 441 extrapolated from the cell line pharmacology screens: the IC 50 and the AUC values of the 442 dose-response curve ( Table S4 ) observed when one compound is applied in vitro to a single 443
cell line sample at successively greater concentrations. Since every cell line possesses a 444 length-4 DRP for a given pair of drugs, the similarity, , between any two cell lines resides 445 on (0,1) and is calculated by a multivariate quasi-Gaussian comparison that differences the 446 elements of the DRPs but also weighs the differences by a combination of local and global 447 network statistics. Similarity between the response vectors, and , is given by: The similarity between two cell lines equals one when both have identical covariate values, 454
and approaches zero as their covariates increasingly differ. Additionally, ( , )= ( , ). 455 Δ , is a 4 1 vector whose entries are the difference of the DRP values in and and β 456 modulates the similarity between two patients. We selected β = 0.5 for our experiments 457
based on experimentation and the observations of previous efforts. The Moore-Penrose pseudo-inverse was used to avoid problems with low-rank during matrix 473
inversion. The framework is generalizable to include more variables and different measures 474 of similarity. The symmeric, positive semi-definite, weighted adjacency matrix, , 475
holds the pairwise similarities. 476 477
Segmentation 478
The set of cell lines, , is segmented recursively into distinct subpopulations using the 479
Fiedler eigenvector derived from the eigendecomposition of 60 . Each parent subpopulation 480 of cell lines is successively segmented into two offspring subpopulations until at least one of 481 3 constraints is satisfied: 482
• The size of the parent subpopulation falls below a user-defined threshold; 483
• The size of either offspring subpopulation is below a user-defined threshold; 484
• The offspring subpopulations are not sufficiently dissimilar, where we measure class 485 separability using the silhouette metric 61 , a common non-parametric method in which 486 values range between -1 (highly similar) and 1 (highly dissimilar) and values near 0 487
indicate the two subpopulations are just barely overlapping. Higher values result in 488 fewer, less granular, subpopulations. 489
In our experiments, we required the size of the parent subpopulation to be at least 40 in 490 order for segmentation to be performed, and required both offspring subpopulations to have 491 20 or more members in order to be retained. The silhouette metric threshold was set to 0.25. 492
Generally, criteria and thresholds can be modified and adapted to emphasize relevant 493 factors in a particular problem. The number of subpopulations in each category were recorded in a 2X2 contingency matrix 522
and using a binomial test compared this to the proportion of cells expected in each category 523
if SEABED segmentation was not performed.
525
After classification of pairwise drug responses, we assessed whether a drug was 526 significantly enriched for one category in comparison with all other drugs. Testing was 527 carried out using the hypergeometric test (phyper R package). 528 529
2-D visualization of drug response profiles 530
To visualize DRPs across cell lines and drug comparisons, we calculated the average 531 log(IC 50 ) values for each drug in subpopulations generated based on their response to the 532 tested drug pairs (Table S5) . We then plotted the mean log(IC 50 ) values as circles on a 2-D 533
scatter plot using the Matplotlib Python library. Dashed lines indicative of local 20th 534 percentile of log(IC 50 ) values for each drug were also plotted on the scatter plot unless stated 535
otherwise. The radii of the circles is proportional to the subpopulation size. Due to potential 536 misidentification, cell lines named 'NA' found in the output files after segmentation with 537 SEABED, were not used for the calculation of the mean log(IC 50 ) values of each 538 subpopulation and hence, not used for the 2-D visualization. 539 540
Tree visualization of subpopulations 541
We utilized tree diagrams to visualize the data generated. The tree diagrams illustrate how 542
the cancer cell lines are segmented into different subpopulations, based on whether they are 543 sensitive or resistant to the drugs that are being tested. We did not visualize further down the 544 tree in the figures when previously observed significant enrichment of genetic biomarkers is 545
no longer observed in all current subpopulations. The tree diagrams were generated through 546
an open-source Python library called Graphviz. The style of each component of the tree 547 diagram was first initialized through a class. This included the colours, shapes, and fonts of 548 the edges and nodes of the tree diagram. A method to create tree diagrams was developed 549
to accept the number of vertices and leaves, the labels for the leaves, and the tree diagram 550
filename. The tree diagram is finally generated and saved by calling the method. 551 552
DATA AND SOFTWARE AVAILABILITY 553 554
All code for the pipeline is open source and available at: https://github.com/szen95/SEABED. 555
All data used in the paper are published previously and publicly available at the GDSC, 556 CCLE, and CTRP databases. Datasets used are listed in Table S4 , Table S5 , and the Key 557
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